Opportunities
Search

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-03-05

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-03-05

Buyer: AOK Nordost. Die Gesundheitskasse. | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-03-05

The purpose of this Funding Opportunity Announcement (FOA) is to support high priority research at the intersection of HIV and substance use. This FOA invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use drugs (PWUD). Applications submitted under this FOA are required to have a detailed research plan, preliminary data, and a clear description of the nexus with substance use. This FOA is open to both individual researchers and research teams and includes all areas of research from basic science to clinical and implementation research. All studies must focus on NIH HIV/AIDS Research Priorities: NOT-OD-20-018: UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding.

The purpose of this Notice of Funding Opportunity (NOFO) is to support investigators who have the interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds (validated hits) for chemical optimization and bioassays for testing new analog compounds.Through this NOFO, NIH wishes to stimulate research in:Discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), National Eye Institute (NEI), and/or National Institute on Aging (NIA) andDiscovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms.Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes.

Buyer: Deutsche Rentenversicherung Knappschaft-Bahn-See | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-03-05

The purpose of this Funding Opportunity Announcement (FOA) is to support high priority research at the intersection of HIV and substance use. This FOA invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use drugs (PWUD). Applications submitted under this FOA are required to have a detailed research plan, preliminary data, and a clear description of the nexus with substance use. This FOA is open to both individual researchers and research teams and includes all areas of research from basic science to clinical and implementation research. All studies must focus on NIH HIV/AIDS Research Priorities: NOT-OD-20-018: UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding.

The goal of this program is to support collaborative translational research projects aligned with NIH efforts to enhance the translation of basic biological discoveries into clinical applications that improve health. It encourages high quality science demonstrating the potential to result in understanding an important disease process or lead to new therapeutic interventions, diagnostics, or prevention strategies within the research interests and priorities of the participating NIH Institutes/Centers (ICs).Specifically, the program seeks to broaden and strengthen translational research collaborations between basic and clinical researchers both within and outside NIH to accelerate and enhance translational science by promoting partnerships between NIH intramural investigators (e.g., those conducting research within the labs and clinics of the NIH) and extramural investigators (e.g., those conducting research in labs outside the NIH), and by providing support for extramural investigators to take advantage of the unique research opportunities available at the NIH Clinical Center by conducting clinical research projects in collaboration with NIH intramural investigators.

Buyer: AB „Kelių priežiūra“ | Notice type: cn-standard | Procedure: restricted | Contract: services | Deadline: 2027-03-07

Buyer: AB „Kelių priežiūra“ | Notice type: cn-standard | Procedure: restricted | Contract: services | Deadline: 2027-03-07

Buyer: AB „Kelių priežiūra“ | Notice type: cn-standard | Procedure: restricted | Contract: services | Deadline: 2027-03-07

Buyer: Ministerie van Defensie | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2027-03-08

Buyer: Ministerie van Defensie | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2027-03-08

Buyer: [SCS] Dirección General de Recursos Económicos del Servicio Canario de la Salud | Notice type: cn-standard | Procedure: restricted | Contract: services | Deadline: 2027-03-09

Buyer: Institut Public Ocens | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2027-03-10

The NIH Cardiovascular Repository for Type 1 Diabetes (CaRe-T1D) was created to improve research on type 1 diabetes (T1D) and cardiovascular disease (CVD). Cardiovascular complications remain the top cause of death among people with T1D and greatly shorten lifespan. The mechanisms underlying atherosclerosis, cardiomyopathy, endothelial dysfunction, and cardiac autonomic neuropathy in T1D remain poorly understood. While managing traditional risk factors—such as high blood glucose, high blood pressure, and elevated cholesterol lower cardiovascular risk, a significant residual risk remains even with optimal control. In addition to atherosclerosis, both diastolic and systolic diabetic cardiomyopathy play a major role in morbidity and mortality among these patients. Currently, no therapies are specifically approved to prevent or treat these common and severe cardiovascular issues in T1D. The purpose of this NOFO is to promote collaborative and interdisciplinary research aimed at enhancing the understanding of the development of CVD in individuals with T1D and the differences with CVD in T1D by continuing the efforts of the CaRe-T1D consortium.This NOFO is associated with the Special Diabetes Program (https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program) which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks.

Buyer: Südtiroler Sanitätsbetrieb - Abteilung Einkäufe | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-03-11

Buyer: COMUTITRES S.A.S. | Notice type: cn-standard | Procedure: oth-mult | Contract: services | Deadline: 2027-03-12

Buyer: UAB "Vilniaus viešasis transportas" | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2027-03-13

Buyer: La Famennoise | Notice type: cn-standard | Procedure: open | Contract: works | Deadline: 2027-03-16

Buyer: Lesy České republiky, s.p. | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2027-03-16

Buyer: Lesy České republiky, s.p. | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2027-03-16

This notice of funding opportunity (NOFO) encourages formative research, intervention development, and pilot-testing of interventions. Primary scientific areas of focus include the feasibility, tolerability, acceptability and safety of novel or adapted interventions that target HIV prevention, treatment or services research for people who use drugs. For the purposes of this NOFO, "intervention" may include behavioral, social, or structural approaches, as well as combination biomedical and behavioral approaches that prevent the acquisition and transmission of HIV infection, or improve clinical outcomes for persons living with HIV.

Buyer: Region Midtjylland | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-03-19

Broad Agency Announcement for Air Delivered Effects - Amendment 5